EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Blood biomarkers in epilepsy

Rakesh Kumar Banote iD, Sarah Akel, Johan Zelano iD

Acta Neurologica Scandinavica · 2022-10 · 146 (4) · 362-368

DOI: 10.1111/ane.13616 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Neurologica Scandinavica, online erschienen am 11.04.2022. Verfasst von Rakesh Kumar Banote und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Epilepsy, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Robust and accessible biomarkers are greatly needed in epilepsy. Diagnostic and prognostic precision in the clinic needs to improve, and there is a need for objective quantification of seizure burden. In recent years, there have been advances in the development of accessible and cost-effective blood-based biomarkers in neurology, and these are increasingly studied in epilepsy. However, the field is in its infancy and specificity and sensitivity for most biomarkers in most clinical situations are not known. This review describes advancements regarding human blood biomarkers in epilepsy. Examples of biochemical markers that have been shown to have higher blood concentrations in study subjects with epilepsy include brain proteins like S100B or neuronal specific enolase, and neuroinflammatory proteins like interleukins, and tumor necrosis factor-alpha. Some of the blood biomarkers also seem to reflect seizure duration or frequency, and levels decrease in response to treatment with antiseizure medication. For most biomarkers, the literature contains seemingly conflicting results. This is to be expected in an emerging field and could reflect different study populations, sampling or analysis techniques, and epilepsy classification. More studies are needed with emphasis put on the classification of epilepsy and seizure types. More standardized reporting could perhaps decrease result heterogeneity and increase the potential for data sharing and subgroup analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpilepsyTumor Necrosis Factor-alphaBiomarkersHumansPhosphopyruvate HydrataseSeizures

Stichwörter der Autor:innen

biomarkerblooddiagnostic studyepilepsyseizure

Substanzen

BiomarkersTumor Necrosis Factor-alphaPhosphopyruvate Hydratase

Autor:innen und Institutionen

  • Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Clinical Neuroscience, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.

ORCID-Profile: Rakesh Kumar Banote, Johan Zelano

Zitieren

APA

Banote, R. K., Akel, S., & Zelano, J. (2022). Blood biomarkers in epilepsy. Acta Neurologica Scandinavica, 146(4), 362-368. https://doi.org/10.1111/ane.13616

Vancouver

Banote RK, Akel S, Zelano J. Blood biomarkers in epilepsy. Acta Neurologica Scandinavica. 2022;146(4):362-368. doi:10.1111/ane.13616

BibTeX
@article{Banote2022,
  author = {Banote, Rakesh Kumar and Akel, Sarah and Zelano, Johan},
  title = {Blood biomarkers in epilepsy},
  journal = {Acta Neurologica Scandinavica},
  year = {2022},
  volume = {146},
  number = {4},
  pages = {362--368},
  doi = {10.1111/ane.13616}
}
Kostenlos starten →